Home
Life Sciences

Sector: Life Sciences

How a patent dispute with 10x helped decimate NanoString’s stock price

Recent $31 million damages award has dealt a further blow to the company's faltering share value

Software, electronics and semiconductors most transacted assets in Q3 2023

The latest AST Patent Deals Report shows assets being transacted by the likes of Huawei and Intel on the sell side, and Philips and Softbank on the buy side

Life Sciences correspondent

Thought leadership from industry experts

Latest updates

EPO Enlarged Board of Appeal confirms use of post-published data to support inventive step

Latest content

Eligibility and PTAB reform bills spark debate at IAM event

IAM Connect: Patent Policy and Litigation delved deeply into Section 101 legislation, reform efforts at the Patent Trial and Appeal Board, and reactions to the European Commission's SEP proposal

23 November 2023

Key Moderna mRNA patent invalidated by EPO

The revocation has major implications for the covid-19 vaccine patent wars

21 November 2023

Qualcomm leads Brazilian patent filings this year

Clarivate data covering 2018 to 2023 reveals a dynamic landscape, including booming industries and Lenovo’s entry into the top 100

17 November 2023

Historic CRISPR drug approval heralds new era in Cas9 IP wars

Green light for first ever Cas9 therapy ushers in next phase of licensing and litigation efforts.

17 November 2023

Regeneron asserts swathe of patents in latest Eylea biosimilar clash

Lawsuit is latest in a torrent of new BPCIA lawsuits to emerge over the past year

16 November 2023

The EU should listen to its Nordic champions, not ignore them

When companies with the innovation and tech leadership credentials of Ericsson, Nokia and Novo Nordisk raise major concerns about Commission proposals, their arguments deserve serious consideration. But it’s not happening. No wonder Europe is losing the global competition race

15 November 2023

Unlock unlimited access to all IAM content